Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (Nasdaq: PGNY) will report its third-quarter 2026 financial results after the market closes on November 4, 2026. The results cover the quarter ended September 30, 2026. A conference call will begin at 4:45 p.m. Eastern Time, following the results release. A live webcast and archive will be available in the Events and Presentations section of the company’s investor website.
Progyny (PGNY) will present menopause research at The Menopause Society 2026 Annual Meeting in San Diego, October 20–24, 2026. The study, conducted with Morehouse School of Medicine, evaluated access, engagement and changes in menopause symptoms among women participating in Progyny’s employer-sponsored Menopause and Midlife program.
Gloria Richard-Davis, a regional dean at Morehouse and member of Progyny’s Medical Advisory Board, will present “Scaling Access to Menopause Care: Real-World Symptom Improvement in an Employer-Sponsored Program” on October 22, from 5:15–5:30 PM PT. Progyny will also exhibit at the meeting.
Progyny (PGNY) expects its annual selling season to contribute 1.2 million new covered lives through launches in the first half of 2027.
The estimate combines commitments already received with anticipated remaining decisions; it is not a count of completed enrollments. Progyny describes the season as pacing toward a potential record for new lives added to its managed fertility solution. For employers seeking to maintain or expand family-building services, the company offers an accelerated contracting path through channel partners.
Progyny (PGNY) will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026, at 11:00 a.m. ET.
The session, led by Chief Financial Officer Mark Livingston, will be webcast live, with audiocasts and replays accessible via the Events and Presentations section of Progyny’s investor relations website.
Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays will be accessible via the Events and Presentations section of Progyny’s investor relations website.
Progyny (Nasdaq: PGNY) reported record second quarter 2026 results, with revenue of $350.5 million, up 5.3% year over year (11.0% excluding a non‑renewing large client), and gross profit of $89.3 million, up 13%. Gross margin expanded to 25.5% from 23.7%.
Net income rose to $28.1 million, or $0.34 per diluted share, versus $17.1 million and $0.19 a year ago. Adjusted EBITDA increased to $62.1 million with a 17.7% margin. Progyny ended June 30, 2026 with $236.9 million in cash and marketable securities, no debt, and working capital of $272.9 million, and had 604 fertility and family building clients. The company repurchased nearly 1.2 million shares in Q2 (2.0 million to date under the May 2026 authorization; 10.8 million across current and prior programs) and guided 2026 revenue to $1.36–$1.385 billion and net income to $104.8–$109.9 million.
Progyny (Nasdaq: PGNY) will report its financial results for the quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A conference call is scheduled for 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time), with a press release issued before the call.
U.S. participants can join by dialing 1.866.825.7331 (passcode 265484); international participants can dial 1.973.413.6106 (same passcode). A replay will be available through August 13, 2026 at 1.800.332.6854 (U.S.) or 1.973.528.0005 (international) with passcode 265484. A live webcast and archive will be accessible via the Events and Presentations section of Progyny’s investor website.
Progyny (Nasdaq: PGNY) released survey results showing strong demand for personalized, human-led guidance in fertility, pregnancy, postpartum, and menopause care.
71% of members reported added stress from their healthcare journey, 43% said stress hurt work performance, and over 70% wanted trusted human support like Progyny Care Advocates (PCAs).
Progyny (Nasdaq: PGNY) announced that its board approved a share repurchase program authorizing buybacks of up to $200 million of common stock. The program will be funded with available cash and may use open-market and Rule 10b5-1 plans, with timing and size depending on market conditions.
Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski and CFO Mark Livingston will speak in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 11:20 a.m. PT / 2:20 p.m. ET.
A live audiocast and replay will be available on Progyny’s investor relations website.